Prelude Therapeutics, Inc. (PRLD)
3.92
+0.04
(+1.16%)
USD |
NASDAQ |
Sep 28, 15:31
Prelude Therapeutics Research and Development Expense (TTM) : 69.43M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 69.43M |
| March 31, 2026 | 79.08M |
| December 31, 2025 | 94.30M |
| September 30, 2025 | 107.93M |
| June 30, 2025 | 115.68M |
| March 31, 2025 | 119.40M |
| December 31, 2024 | 118.00M |
| September 30, 2024 | 116.71M |
| June 30, 2024 | 113.51M |
| March 31, 2024 | 108.97M |
| December 31, 2023 | 103.39M |
| September 30, 2023 | 98.93M |
| June 30, 2023 | 95.56M |
| Date | Value |
|---|---|
| March 31, 2023 | 91.90M |
| December 31, 2022 | 92.89M |
| September 30, 2022 | 92.20M |
| June 30, 2022 | 92.03M |
| March 31, 2022 | 93.13M |
| December 31, 2021 | 86.78M |
| September 30, 2021 | 76.17M |
| June 30, 2021 | 68.74M |
| March 31, 2021 | 56.11M |
| December 31, 2020 | 48.18M |
| September 30, 2020 | 42.45M |
| June 30, 2020 | 32.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Q32 Bio, Inc. | 14.35M |
| Intellia Therapeutics, Inc. | 337.63M |
| Twist Bioscience Corp. | 71.86M |
| Beam Therapeutics, Inc. | 408.66M |
| Revolution Medicines, Inc. | 1.287B |